Paul Robinson
Research Subjects
Paul Robinson has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Kielhorn
Eli Lilly Europe, Surrey, UK
1 shared publication - Alissa Brown
M-Tag Limited, Level 3, 109, Hammersmith Road, London, W14 OQH, UK
1 shared publication - Dominic Tilden
M-TAG, London, UK
1 shared publication - Hans von der Maase
Department of Oncology, Aarhus University Hospital, Denmark
1 shared publication Michael Aristides
M-Tag Limited, Level 3, 109, Hammersmith Road, London, W14 OQH, UK
1 shared publication- Shkun Bhalla
Former employee of Eli Lilly, UK, Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL, UK
1 shared publication
Latest Publications
- 1 February 2004
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 4 (1) , 27-38
Cost–utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer
A cost–utility analysis was conducted to compare the gemcitabine (Gemzar®)/cisplatin and methotrexate/vinblastine(Velban®)/doxorubicin (Doxil®)/cisplatin regimens in the treatment of locally advanced or metastatic bladder cancer. The analysis combined theresults of a cost analysis of a head-to-head Phase III clinical trial with those from a cross-sectional utility study. The analysis was performed from the perspective of the National Health Service in England and Wales. Medical resource use was obtained from the clinical trial database, from which patient-level cost streams were estimated for each treatment group. Unit costs for each resource utilization component were sought from the latest UK cost sources available at the time of analysis (2001). The distribution of the mean total and incremental costs for each group was simulated via bias-adjusted bootstrapping. Time trade-off utilities were derived from the utility study, which aimed to value the superior toxicity profile associated with gemcitabine/c...
- 1 February 2004
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 4 (1) , 27-38
Cost–utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer
A cost–utility analysis was conducted to compare the gemcitabine (Gemzar®)/cisplatin and methotrexate/vinblastine(Velban®)/doxorubicin (Doxil®)/cisplatin regimens in the treatment of locally advanced or metastatic bladder cancer. The analysis combined theresults of a cost analysis of a head-to-head Phase III clinical trial with those from a cross-sectional utility study. The analysis was performed from the perspective of the National Health Service in England and Wales. Medical resource use was obtained from the clinical trial database, from which patient-level cost streams were estimated for each treatment group. Unit costs for each resource utilization component were sought from the latest UK cost sources available at the time of analysis (2001). The distribution of the mean total and incremental costs for each group was simulated via bias-adjusted bootstrapping. Time trade-off utilities were derived from the utility study, which aimed to value the superior toxicity profile associated with gemcitabine/c...